New Amylin Agonist Shows Potent Metabolic Benefits Beyond GLP-1 Pathways

Type 2 Diabetes and obesity remain major global health challenges, with current treatments like GLP-1 receptor agonists (gut hormones that stimulate insulin release) showing significant but often incomplete efficacy, particularly in achieving sustained weight loss and comprehensive metabolic improvements. While amylin is a naturally occurring hormone co-secreted with insulin, its therapeutic potential through selective receptor agonism has been underexplored beyond its natural synergy with incretins. This study aimed to evaluate the distinct metabolic advantages of a novel, selective amylin receptor agonist, AMY-123, specifically investigating its efficacy independent of or superior to incretin pathways in models of metabolic dysfunction.

In DIO mice, AMY-123 at 0.1 mg/kg led to a remarkable 28% reduction in body weight compared to controls (p<0.001), significantly outperforming the GLP-1 agonist which achieved a 19% reduction (p<0.05). This was accompanied by a 45% decrease in cumulative food intake (p<0.001) and a 3.2-fold improvement in glucose tolerance. Furthermore, AMY-123 treatment resulted in a 2.5-fold increase in energy expenditure and a 1.8-fold upregulation of brown adipose tissue markers (indicators of fat-burning tissue), suggesting a distinct mechanism of action. Plasma triglyceride levels were reduced by 35% (p<0.01) in the high-dose AMY-123 group compared to vehicle. The most striking finding was that AMY-123 significantly reduced hepatic steatosis (fatty liver) by 60% and improved insulin sensitivity by 55% in NHP, effects that were 2-fold greater than those typically observed with incretin mimetics in similar models.